<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527043</url>
  </required_header>
  <id_info>
    <org_study_id>1608017504</org_study_id>
    <nct_id>NCT03527043</nct_id>
  </id_info>
  <brief_title>Impact of Escitalopram on Sperm DNA Fragmentation</brief_title>
  <official_title>Assessing the Impact of Escitalopram on Sperm DNA Fragmentation: A Randomized Placebo Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind placebo-controlled randomized trial of daily escitalopram for 6 weeks in healthy
      men with normal semen analyses and no psychiatric history of depression, bipolar, mania or
      suicidal ideation. Hormone profiles, semen analysis, sperm DNA fragmentation, and sexual
      function will be measured at baseline, after 6 weeks of therapy, and 4 weeks after
      discontinuation of therapy (10 weeks into study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SSRI medications, specifically escitalopram is a very commonly prescribed medication among
      men of reproductive age. Significant evidence exists that they may be harmful for paternal
      fertility potential in both animal and human studies. However, high quality data is lacking,
      particularly among commonly used SSRI's such as escitalopram. As such, it is important to
      properly evaluate the potential effect of escitalopram in a randomized placebo controlled
      fashion. Results will be important in guiding urologists, psychiatrists and family
      practitioners regarding discussion surrounding SSRI use in their patients interested in
      fertility.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients converted from normal to abnormal sperm DNA fragmentation from baseline to 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>TUNEL assay for sperm DNA fragmentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sperm DNA fragmentation from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>TUNEL assay for sperm DNA fragmentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in sperm motility from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Percentage of motile sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in progressive motility from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Percentage of progressive motile sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in viability from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Percentage of viable sperm in semen analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in concentration from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Sperm concentration (number of sperm/mL) in semen analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum testosterone (ng/dL) from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Serum testosterone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum luteinizing hormone (LH) (mIU/mL) from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Serum Luteinizing hormone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum follicle-stimulating hormone (FSH) (mIU/mL) from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>Serum follicle-stimulating hormone measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in serum prolactin (ng/mL) from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>serum prolactin measurement</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in International Index of Erectile Function Survey from baseline to 6 and 10 weeks</measure>
    <time_frame>0, 6, 10 weeks</time_frame>
    <description>International Index of Erectile Function Survey</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Sperm DNA Fragmentation</condition>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg by mouth daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo control by mouth for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10mg by mouth daily for 6 weeks</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matched placebo control by mouth for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal semen analyses, or semen analyses with at least 5 million sperm

          -  Normal TUNEL value (&lt;7%)

          -  Willing to engage in at least weekly sexual activity, with a partner or alone for the
             duration of the 10-week study

        Exclusion Criteria:

          -  Azoospermia or severe oligospermia (&lt;5million sperm per semen analysis)

          -  Presently attempting to conceive pregnancy

          -  Sexual dysfunction preventing ability to provide semen analysis throughout study or
             engage in weekly sexual activity

          -  Current psychiatric disorder including: bipolar, mania, depression, generalized
             anxiety, social phobia, panic attacks, obsessive compulsive disorder, and
             schizophrenia.

          -  Family history of bipolar disorder, or suicide (including 2nd degree relatives)

          -  Present use of psychotropic agents (prescription or herbal) or anticonvulsants

          -  Use of sleeping pills

          -  Alcohol consumption greater that 2oz/day

          -  Use of illicit drugs

          -  Inability to read, follow instructions or complete questionnaires in English.

          -  Use of hormonal medications in past 3 months (androgens, androgen blockade, anabolic
             steroids, estrogens, herbal)

          -  Use of medications to enhance sexual function

          -  History of chemotherapy or pelvic radiation

          -  Use of Monoamine Oxidase inhibitors (MAOi's) or tricyclic antidepressants (TCAs)
             within 14 days

          -  Liver disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Flannigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Schlegel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Phil Bach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adaobi Onunkwo</last_name>
    <phone>646-962-0534</phone>
    <email>ado2007@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Carter</last_name>
    <phone>(212) 746-5706</phone>
    <email>juc2032@med.cornell.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Carter</last_name>
    </contact>
    <investigator>
      <last_name>Ryan Flannigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Goldstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Kashanian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Schlegel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darius Paduch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

